Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022105041 - APPLICATION OF MIR-325 NUCLEIC ACID ANALOG IN PREPARATION OF RELATED PRODUCT FOR TREATING SINUSOIDAL ENDOTHELIAL CELL PATHOLOGICAL DYSFUNCTION

Publication Number WO/2022/105041
Publication Date 27.05.2022
International Application No. PCT/CN2021/000004
International Filing Date 04.01.2021
IPC
A61K 31/7105 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 35/28 2015.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61P 5/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
A61P 7/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
A61P 9/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
CPC
A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 35/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
18for pancreatic disorders, e.g. pancreatic enzymes
Applicants
  • 西安组织工程与再生医学研究所 XI'AN INSTITUTE OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE [CN]/[CN]
Inventors
  • 李丽雅 LI, Liya
  • 刘文佳 LIU, Wenjia
Priority Data
202011291870.018.11.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) APPLICATION OF MIR-325 NUCLEIC ACID ANALOG IN PREPARATION OF RELATED PRODUCT FOR TREATING SINUSOIDAL ENDOTHELIAL CELL PATHOLOGICAL DYSFUNCTION
(FR) APPLICATION D'ANALOGUE D'ACIDE NUCLÉIQUE DE MIR-325 DANS LA PRÉPARATION D'UN PRODUIT APPARENTÉ POUR LE TRAITEMENT D'UN DYSFONCTIONNEMENT PATHOLOGIQUE DE CELLULES ENDOTHÉLIALES SINUSOÏDALES
(ZH) miR-325核酸类似物在制备治疗血窦内皮细胞病理性功能异常相关产品中的应用
Abstract
(EN) Provided is an application of an miR-325 nucleic acid analog in the preparation of a related product for treating sinusoidal endothelial cell pathological dysfunction. By directly or indirectly affecting signal pathways by means of miR-325, including recovering the expressions of genes stabilin-2, PTPRM, YWHAQ, etc., of cells, the sinusoidal endothelial cells are re-differentiated to promote the capacity of the sinusoidal endothelial cells for regulating inflammations and resisting activation of stellate cells, thereby effectively relieving vascular diseases.
(FR) L'invention concerne une application d'un analogue d'acide nucléique de miR-325 dans la préparation d'un produit apparenté pour le traitement d'un dysfonctionnement pathologique de cellules endothéliales sinusoïdales. En affectant directement ou indirectement les voies de signalisation au moyen de miR-325, y compris la récupération des expressions de gènes stabiline-2, PTPRM, YWHAQ, etc., de cellules, on redifférencie les cellules endothéliales sinusoïdales pour favoriser la capacité des cellules endothéliales sinusoïdales à réguler les inflammations et résister à l'activation de cellules stellaires, ce qui permet de soulager efficacement les maladies vasculaires.
(ZH) 提供了miR-325核酸类似物在制备治疗血窦内皮细胞病理性功能异常相关产品中的应用。通过miR-325直接和间接影响的信号通路,包括恢复细胞stabilin-2,PTPRM,YWHAQ等基因的表达,使血窦内皮细胞重新分化,促进血窦内皮细胞调节炎症,抗星状细胞激活的能力,从而使所述血管性病变得到有效缓解。
Related patent documents
Latest bibliographic data on file with the International Bureau